Showing results (11-20 of 163) with videos related to
Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|June 9, 2026
Current challenges in standardising classification and management of locally advanced cutaneous squamous cell carcinomaSophia Kreft, Berenice M Lang, Mario Mandalà, et al.Frontiers in Immunology|December 20, 2024
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinomaValerie Glutsch, Patrick Schummer, Matthias Goebeler, et al.Plos One|August 5, 2015
Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host DiseaseCindy Franklin, Elvir Cesko, Uwe Hillen, et al.Cancer Cell|March 25, 2022
CD8<sup>+</sup> T cells PUF(A)ing the flames of cancer ferroptotic cell deathJosé Pedro Friedmann Angeli, Thamara Nishida Xavier da Silva, Bastian SchillingJournal of Immunological Methods|April 26, 2011
Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsetsPatrick J Schuler, Malgorzata Harasymczuk, Bastian Schilling, et al.Dermatopathology (Basel, Switzerland)|June 1, 2022
PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid MelanomaValerie Glutsch, Marion Wobser, Bastian Schilling, et al.Journal for Immunotherapy of Cancer|July 14, 2019
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapyValerie Glutsch, Franziska Grän, Judith Weber, et al.Journal of Molecular Medicine (Berlin, Germany)|September 15, 2011
IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment modelBastian Schilling, Malgorzata Harasymczuk, Patrick Schuler, et al.Journal of Immunological Methods|April 24, 2012
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samplesAthanasios Kotsakis, Malgorzata Harasymczuk, Bastian Schilling, et al.Seminars in Oncology|November 16, 2010
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their managementKatharina C Kaehler, Sarah Piel, Elisabeth Livingstone, et al.Pageof 17